Understanding Challenges and Needs in Refractory Chronic GVHD

Insights from 2023 ASH Annual Meeting
D

Chronic GVHD: Results from Agave-201 - Axatilimab at 3 Different Doses

By Insights from 2023 ASH Annual Meeting FEATURING Daniel Wolff
By Insights from 2023 ASH Annual Meeting FEATURING Daniel Wolff
94 views
December 29, 2023
Comments 0
Login to view comments. Click here to Login
06:18

CSF1R's Role in Modulating Inflammation and Fibrosis in cGVHD

Robert Zeiser

49 views
23:37

Management of Viral Infections Post-Transplant: CMV, EBV, and HHV-6

Rush University Medical Center

E. Bhaimia

329 views
07:22

Steroid-Refractory GvHD Management: When to Switch From Steroids

Giuseppe Francesco Milone

73 views
46:03

CAR NK Cells: Next Generation Cell Therapies for Cancer

University of Colorado Cancer Center

K. Rezvani

268 views
08:08

Unmet Needs in GvHD and the Role of Axatilimab

Jose Perez Simon

75 views
08:43

Maintaining QoL in Chronic GvHD

Nandita Khera

49 views
17:18

Approaches to Preventing and Treating GVHD in 2024

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

N. Hossain

132 views
14:19

Axatilimab in Chronic GVHD: Updates From the AGAVE-201 Study

Zachariah DeFilipp

170 views
27:21

Updates in Transplantation and GVHD From Recent Meetings

UChicago Medicine

M. Nawas

52 views
31:53

HSCT in 2024: What Every Hematologist Needs to Know

Indy Hematology Review

R. Childs

724 views
14:54

Clonal Hematopoiesis Is Common in Unrelated Stem Cell Donors but Has…

Insights from 2023 ASH Annual Meeting

J. Schetelig

52 views